Schedule 13G ownership disclosure

CHROMOCELL THERAPEUTICS CORP

Security class unavailable · CUSIP: 171126105

Event date: 2024-02-21

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
483,406
Percent of class
8.4000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001753926-24-000443
Form type
SC 13G
Filer
Pelthos Therapeutics Inc.
CIK
CIK 1919246
Filed
Mar 01, 2024
Reporting period
Feb 21, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub